URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$28.74
−16.45%Forward multiples
Based on analyst estimates
- P/E forward
- 13.44x
- P/E 2026E
- —
- P/E 2027E
- 10.64x
- P/E 2028E
- 6.07x
- P/S forward
- 2.89x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -10.61x
- Price / sales
- 7.44x
- Price / cash flow
- -8.84x
Enterprise value
- Enterprise value
- $1.5B
- EV / sales
- 7.91x
- EV / EBITDA
- -21.29x
- EV / EBIT
- -22.40x
- Market cap
- $1.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026